Acceleron Pharma recently presented data on two biomarkers that the company is exploring as part of its strategy to advance personalized drugs for breast and squamous cell head and neck cancer patients.

At the American Society of Clinical Oncology's recent 2012 Markers in Cancer conference, researchers from Acceleron and elsewhere presented data from a study in which patients who had elevated serum levels of the protein activin lived for a shorter time after treatment with Herceptin-containing therapies than those with low levels of the protein.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.